Remestemcel-L allogeneic bone marrow-derived mesenchymal stem cell product to treat medically refractory Crohn's colitis: preliminary phase IB/IIA study

Br J Surg. 2022 Jul 15;109(8):653-655. doi: 10.1093/bjs/znac078.

Authors

Amy L Lightner¹, Justin Ream², Douglas Nachand², Clifton Fulmer³, Miguel Regueiro¹, Scott R Steele¹

Affiliations

¹ Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio, USA.
² Department of Radiology, Imaging Institute, Cleveland Clinic, Ohio, USA.
³ Department of Pathology, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio, USA.

PMID: 35714218
DOI: 10.1093/bjs/znac078

No abstract available

Publication types

Clinical Trial, Phase I
Clinical Trial, Phase II

MeSH terms

Biological Products
Bone Marrow
Colitis*
Crohn Disease* / therapy
Hematopoietic Stem Cell Transplantation*
Humans
Mesenchymal Stem Cell Transplantation*
Mesenchymal Stem Cells*

Substances

Biological Products
remestemcel-l